Shelton Wealth Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Shelton Wealth Management LLC purchased a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 22,199 shares of the biotechnology company’s stock, valued at approximately $893,000.

A number of other hedge funds also recently made changes to their positions in VKTX. Signaturefd LLC raised its holdings in shares of Viking Therapeutics by 16.2% in the 3rd quarter. Signaturefd LLC now owns 1,351 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 188 shares during the period. Stone House Investment Management LLC grew its stake in Viking Therapeutics by 66.7% in the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 200 shares in the last quarter. Keudell Morrison Wealth Management boosted its holdings in shares of Viking Therapeutics by 5.9% in the third quarter. Keudell Morrison Wealth Management now owns 4,306 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 241 shares during the period. GAMMA Investing LLC raised its stake in shares of Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 243 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its holdings in Viking Therapeutics by 84.3% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 253 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors.

Viking Therapeutics Trading Up 0.3 %

Shares of VKTX opened at $32.65 on Friday. The stock has a fifty day moving average price of $46.21 and a 200-day moving average price of $55.99. Viking Therapeutics, Inc. has a 12 month low of $20.47 and a 12 month high of $99.41. The firm has a market cap of $3.64 billion, a PE ratio of -35.11 and a beta of 0.95.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. During the same period last year, the firm posted ($0.23) EPS. As a group, research analysts forecast that Viking Therapeutics, Inc. will post -0.97 EPS for the current year.

Analysts Set New Price Targets

VKTX has been the subject of several recent analyst reports. B. Riley initiated coverage on shares of Viking Therapeutics in a research note on Friday, November 22nd. They set a “buy” rating and a $109.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Friday. William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Finally, Piper Sandler began coverage on shares of Viking Therapeutics in a research report on Monday, December 2nd. They issued an “overweight” rating and a $74.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $106.75.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 11,000 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $80.89, for a total value of $889,790.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at $768,455. The trade was a 53.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Greg Zante sold 50,309 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the sale, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. This represents a 23.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 443,701 shares of company stock valued at $23,898,520 over the last 90 days. 4.70% of the stock is currently owned by corporate insiders.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.